De novo lipogenesis (DNL) is paradoxically up-regulated by its end product, saturated fatty acids (SAFAs). We tested the hypothesis that SAFA-induced up-regulation of DNL reflects coordinate up-regulation of elongation and desaturation pathways for disposal of SAFAs and production of monounsaturated fatty acids to protect cells from SAFA toxicity. Human preadipocytes were differentiated in vitro for 14 days with [U-13 C]palmitate (0 -200 M) to distinguish exogenous fatty acids from those synthesized by DNL. Exogenous palmitate up-regulated DNL (p < 0.001) concomitantly with SCD and elongation (each p < 0.001). Adipocytes from some donors were intolerant to high palmitate concentrations (400 M). Palmitate-intolerant cells showed lower TG accumulation. They had lower expression of SCD mRNA and less monounsaturated fatty acids in TG, emphasizing the importance of desaturation for dealing with exogenous SAFAs. There was greater [U-13 C]palmitate incorporation in phospholipids. SCD knockdown with small interfering RNA caused down-regulation of DNL and of expression of DNLrelated genes, with reduced membrane fluidity (p < 0.02) and insulin sensitivity (p < 0.01), compared with scrambled small interfering RNA controls. There was preferential channeling of DNL-derived versus exogenous palmitate into elongation and of DNL-derived versus exogenous stearate into desaturation. DNL may not act primarily to increase fat stores but may serve as a key regulator, in tandem with elongation and desaturation, to maintain cell membrane fluidity and insulin sensitivity within the human adipocyte.In many cell types, including pancreatic -cells and endothelial cells, the saturated fatty acid (SAFA) 2 palmitate can have adverse effects on cell function, including endoplasmic reticulum stress and apoptosis (1-4). Palmitate-induced apoptosis can be rescued by the monounsaturated fatty acids (MUFAs) palmitoleate (16:1 n-7) and oleate (18:1 n-9), preventing apoptosis and increasing fatty acid storage as triglyceride (TG) (5, 6). Additionally, the adverse effects of an overabundance of saturated fatty acids have been well documented in humans (7,8).De novo lipogenesis (DNL) is the formation of lipids from nonfat precursors such as glucose and produces the SAFAs myristate (14:0, a minor end product) and palmitate (16:0, the main end product). Palmitate and stearate (18:0) are substrates for stearoyl-CoA desaturase (SCD, or ⌬-9 desaturase), which acts to convert these SAFAs to MUFAs palmitoleate and oleate, respectively. In the liver, the pathways of DNL and fatty acid desaturation by SCD appear to be coordinately regulated (9). Therefore, it would seem that SCD plays a crucial role in maintaining the intracellular equilibrium of SAFAs and MUFAs. However, the literature surrounding the role of SCD in cell function and disease is conflicting.Paradoxically, SAFAs have been shown to up-regulate lipogenesis. Early studies in rats showed palmitate to stimulate glucose incorporation into TG fatty acids (10, 11). Several studies of high fat feeding ...